Drug interactions
Eribulin + Indacaterol-glycopyrronium
Severity: Moderate
Eribulin and Indacaterol-glycopyrronium: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Eribulin can prolong the QT interval, and indacaterol may modestly add to repolarization effects, particularly with low potassium. The combination may increase the risk of ventricular arrhythmias in susceptible patients.
What this interaction means in plain words
Eribulin and Indacaterol-glycopyrronium can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Eribulin belongs to Oncology; Indacaterol-glycopyrronium belongs to Respiratory.
Why it happens
Additive effects on cardiac repolarization.
What to do
Monitor ECG and electrolytes in patients with cardiac risk factors or other QT-prolonging drugs. Correct hypokalemia and hypomagnesemia before and during eribulin treatment.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Eribulin and Indacaterol-glycopyrronium, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Indacaterol-glycopyrronium
Other interactions of Eribulin
Frequently asked questions
Can I take Eribulin with Indacaterol-glycopyrronium?
MediHelp rates the interaction as moderate. Eribulin and Indacaterol-glycopyrronium can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Eribulin can prolong the QT interval, and indacaterol may modestly add to repolarization effects, particularly with low potassium. The combination may increase the risk of ventricular arrhythmias in susceptible patients.
How serious is the interaction between Eribulin and Indacaterol-glycopyrronium?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor ECG and electrolytes in patients with cardiac risk factors or other QT-prolonging drugs. Correct hypokalemia and hypomagnesemia before and during eribulin treatment.
What other medicines interact with Indacaterol-glycopyrronium?
MediHelp also lists interactions of Indacaterol-glycopyrronium with, for example, Amisulpride, Arformoterol, Arsenic trioxide. The full list is on the Indacaterol-glycopyrronium page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
